A detailed history of Soleus Capital Management, L.P. transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 399,982 shares of YMAB stock, worth $3.24 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares
399,982
Previous 647,982 38.27%
Holding current value
$3.24 Million
Previous $7.83 Million 32.91%
% of portfolio
0.45%
Previous 0.79%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$9.95 - $15.39 $2.47 Million - $3.82 Million
-248,000 Reduced 38.27%
399,982 $5.25 Million
Q2 2024

Aug 14, 2024

BUY
$11.6 - $17.25 $893,200 - $1.33 Million
77,000 Added 13.49%
647,982 $7.83 Million
Q1 2024

May 15, 2024

BUY
$6.57 - $18.69 $2.72 Million - $7.73 Million
413,800 Added 263.26%
570,982 $9.28 Million
Q2 2023

Aug 14, 2023

BUY
$5.68 - $10.34 $397,600 - $723,800
70,000 Added 80.29%
157,182 $1.07 Million
Q3 2022

Nov 14, 2022

SELL
$13.96 - $19.67 $684,040 - $963,830
-49,000 Reduced 35.98%
87,182 $1.26 Million
Q2 2022

Aug 15, 2022

SELL
$8.22 - $15.13 $845,016 - $1.56 Million
-102,800 Reduced 43.02%
136,182 $2.06 Million
Q1 2022

May 16, 2022

SELL
$6.55 - $17.42 $468,403 - $1.25 Million
-71,512 Reduced 23.03%
238,982 $2.84 Million
Q4 2021

Feb 14, 2022

BUY
$15.51 - $29.31 $694,754 - $1.31 Million
44,794 Added 16.86%
310,494 $5.03 Million
Q3 2021

Nov 15, 2021

BUY
$27.47 - $37.31 $3.33 Million - $4.53 Million
121,400 Added 84.13%
265,700 $7.58 Million
Q2 2021

Aug 16, 2021

BUY
$25.45 - $37.64 $3.67 Million - $5.43 Million
144,300 New
144,300 $4.88 Million

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $355M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Soleus Capital Management, L.P. Portfolio

Follow Soleus Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Soleus Capital Management, L.P. with notifications on news.